Transient receptor potential (TRP) channels are an important class of receptors widely distributed in the mammalian central and peripheral nervous systems. TRP receptors have been shown to be activated and regulated by a variety of stimuli including temperature, mechano-stimulation, divalent cations, pH and different kinds of molecules, which mediate the sensation of taste. Dysfunction of TRP channels can cause various pathological conditions, including an inherited pain syndrome, multiple kidney diseases and skeletal disorders. Hence, TRP channels become potential targets for the treatment of such disorders. Currently within drug development, much attention is paid to the TRP ankyrin 1 (TRPA1) channel. Preclinical data and data from a recent human genetic study1 highlight TRPA1 antagonists as a promising new approach for the treatment of acute and chronic pain. Patch clamp electrophysiology remains the gold standard for studying ion channels. We have employed planar patch clamp instrumentation for medium and high-throughput screening (Patchliner and SyncroPatch 96 platforms) to study the TRPA1 channel stably expressed in HEK cells. TRPA1 is activated by a range of environmental irritants, pungent compounds found in foods, as well as metabolites produced during oxidative stress. Here, we demonstrate the activation of TRPA1 by mustard and cinnamon. Induced currents could be reversibly blocked by the potent antagonist HC030031. The most challenging characteristics of TRPA1 within screening are the channels` mechano-sensitivity, fast desensitization and its regulation by intracellular calcium. Using a combination of excellent fluidics, allowing for fast solution exchange whilst brief compound application, and the usage of calcium buffered external solution, we have achieved recording of high quality data with a high success rate for obtaining stable giga-seals (typically 60 to 80%), and reliable pharmacology.
37th Congress of IUPS (Birmingham, UK) (2013) Proc 37th IUPS, PCB111
Poster Communications: TR(i)P to automation
I. Rinke1, C. Haarmann1, N. Becker1, A. Obergrussberger1, S. Stölzle1, A. Brüggemann1, M. George1, N. Fertig1
1. Nanion Technologies, Munich, Germany.
View other abstracts by:
Where applicable, experiments conform with Society ethical requirements.